Neurochem to begin Phase II/III

Neurochem (TSE:NRM) submitted an IND to begin a pivotal Phase II/III study of its Fibrillex oral anti-amyloid agent to treat secondary amyloidosis. Fibrillex has Orphan Drug designation for the indica...